Alanosine

Alanosine
Clinical data
ATC code	None;
Identifiers
	IUPAC name (S)-2-Amino-3-[hydroxy(nitroso)amino]propanoic acid;
CAS Number	5854-93-3 ;
PubChem CID	22128;
ChemSpider	20787 ;
UNII	2CNI71214Y;
ChEMBL	ChEMBL452715 ;
CompTox Dashboard (EPA)	DTXSID501024175 ;
Chemical and physical data
Formula	C3H7N3O4
Molar mass	149.106 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(O)[C@@H](N)CN(O)N=O;
	InChI InChI=1S/C3H7N3O4/c4-2(3(7)8)1-6(10)5-9/h2,10H,1,4H2,(H,7,8)/t2-/m0/s1 ; Key:MLFKVJCWGUZWNV-REOHCLBHSA-N ;
	(verify)

Alanosine (also called SDX-102)^[1] is a substance that has been studied for the treatment of pancreatic cancer.^[2] It is an antimetabolite. It is used as one of a few experimental treatments for patients with deadly pancreatic cancer when the main chemotherapeutic treatment regimen of gemcitabine is no longer useful.^{[needs update]}

References

^ PubChem. "Alanosine". pubchem.ncbi.nlm.nih.gov. Retrieved 2021-04-08.
^ Yu J (November 2001). "Alanosine (UCSD)". Current Opinion in Investigational Drugs. 2 (11): 1623–30. PMID 11763167.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

[1] PubChem. "Alanosine". pubchem.ncbi.nlm.nih.gov. Retrieved 2021-04-08.

[2] Yu J (November 2001). "Alanosine (UCSD)". Current Opinion in Investigational Drugs. 2 (11): 1623–30. PMID 11763167.

[1]

[2]